definiens: or are defined in Section 1.26 ), Argos wishes CELLSCRIPT to : ( A)Develop cGMP processes for Production of the Argos Product, and GMP processes for Production ofthe following materials : ( i)pARG CD40L [ * * ] E. coli CS10 Master Cell Bank ; ( ii)pARG CD40L [ * * ] Plasmid ; ( iii)Linearized pARG CD40L [ * * ] Plasmid ; and ( iv)Uncapped CD40L MET1 [ * * ] RNA ; wherein ( i ) to ( iv ) are collectively the ; ( B)Produce the Critical Starting Materials for the Argos Product and the Argos Product using said cGMPprocesses developed pursuant to Section I.(A ) ; ( C)Provide to Argos sufficient quantities of pARG CD40L [ * * ] Plasmid Produced by CELLSCRIPT inorder to enable Argos to perform comparability studies to qualify use of said CELLSCRIPT - Producedplasmid for Argos ’ manufacturing of the Argos Product until such time as Argos has performedcomparability studies of Argos Product Produced by CELLSCRIPT to qualify Argos ’ use of saidCELLSCRIPT - Produced Argos Product for Argos ’ manufacturing of Argos ’ Arcelis ® autologousvaccines, it being understood that CELLSCRIPT will provide reasonable quantities of saidCELLSCRIPT - Produced plasmid to Argos at no cost through [ * * ] solely for Argos ’ use in thecomparability and qualification studies, and thereafter, the Parties will negotiate a price for saidCELLSCRIPT - Produced plasmid if Argos wishes to purchase said plasmid for Argos ’ manufacturingof the Argos Product ; Page 1 of 45 ( D)Sell Argos Product Produced by CELLSCRIPT to Argos for use as a Critical Raw Material in Argos’manufacturing of Argos ’ Arcelis ® autologous vaccines ; and ( E)Sell CELLSCRIPT ’s Kits to Argos for use by Argos for manufacturing amplified mRNA for Argos’Arcelis ® autologous vaccines or for manufacturing the Argos Product until such time as Argos canpurchase the Argos Product made using cGMP processes from CELLSCRIPT ; and II . In accordance with the Project Work Agreement ( PWA ) between the Parties, CELLSCRIPT wishes to : ( A)Develop cGMP processes for Production of Critical Starting Materials for the Argos Product and theArgos Product, in accordance with the PWA ; ( B)Produce Critical Starting Materials for the Argos Product and the Argos Product using said cGMPprocesses developed pursuant to Section II.(A ) ; ( C)Provide to Argos sufficient quantities of pARG CD40L [ * * ] Plasmid Produced by CELLSCRIPT inorder to enable Argos to perform comparability studies to qualify use of said CELLSCRIPT - Producedplasmid for Argos ’ manufacturing of the Argos Product until such time as Argos has performedcomparability studies of Argos Product Produced by CELLSCRIPT to qualify Argos ’ use of saidCELLSCRIPT - Produced Argos Product for Argos ’ manufacturing of Argos ’ Arcelis ® autologousvaccines, it being understood that CELLSCRIPT will provide reasonable quantities of saidCELLSCRIPT - Produced plasmid to Argos at no cost through [ * * ] solely for Argos ’ use for thecomparability and qualification studies, and thereafter, the Parties will negotiate a price for saidCELLSCRIPT - Produced plasmid if Argos wishes to purchase said plasmid for Argos ’ manufacturingof the Argos Product ; and ( D)Sell Argos Product Produced by CELLSCRIPT to Argos for use as a Critical Raw Material in Argos’manufacturing of Argos ’ Arcelis ® autologous vaccines ; and ( E)Sell CELLSCRIPT ’s Kits to Argos for use by Argos for manufacturing amplified mRNA for Argos’Arcelis ® autologous vaccines or for manufacturing the Argos Product until such time as Argos canpurchase the Argos Product made using cGMP processes from CELLSCRIPT